Berlin, 20th October, 2017 – The EU-funded Optogenerapy project was presented at the XXV Anniversary Congress of the European Society of Gene and Cell Therapy (ESGCT), which took place the 17th – 20th of October 2017 in Berlin, Germany. During the second day of the Congress, partners exhibited the poster “Bio-electronic cell-based implant to deliver beta interferon”, explaining the methodology and objectives behind the project.
For Optogenerapy project this has represented a great opportunity to showcase the novel optogenetics implant for controlled beta interferon (IFN-β) protein delivery developed within the project for treating patients suffering from multiple sclerosis.
The conference gathered together industry leaders in the development of cellular and gene therapies, manufacturing companies, top scientists and clinicians in the fields of cell-based and gene-based therapies together with regulatory bodies in Europe.
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.